Biohealthmatics.com Biomedical Informatics at OHSU
advertisement
Sign Up  
Biohealthmatics Centers
Home
Jobs Search
Career Center
Networking Center
Company Profiles
Knowledge Center
Industry News
Web Directory
Industry Books
Featured Articles

Biohealthmatics.com....linking professionals
advertisement

Join Us

Link To Us





Jobs Search Home - Companies Categories



Neurochem
Address: 275 Armand-Frappier Boulevard
Laval
QC
Canada
H7V 4A7
Phone Number: 450-680-4500
Website: http://www.neurochem.com/
Year Founded: 1993
Ownership: Public (NASDAQ (GM): NRMX; Toronto: NRM)

Company Overview:
Neurochem Inc. is a dynamic, highly energized biopharmaceutical company that is motivated by it search and development programs which seek to expand the realm of novel therapeutics. The company is located in the Parc scientifique et de haute technologie de Laval, in Quebec, Canada. It is Neurochem's primary strategic plan to focus strongly on the further development of an expanding pipeline of product candidates that are designed to address vital unmet medical needs. Most of Neurochem’s present focus involves drug candidates for the treatment of neurological diseases.

The company has promising potential drug candidates still being held in clinical trials that include disorder like AA amyloidosis, Alzheimer's disease, and hemorrhagic stroke due to cerebral amyloid angiopathy. Yet, the company is just gaining momentum and more treatment emphases will emerge as the company continues to expand.

The company was founded in 1993 by the technology transfer office of Queen's University, Parteq Research and Development Innovations, in Kingston, Ontario, Canada, to develop and commercialize small organic molecules. These molecules, discovered by lead researchers at the University, establish the heart of Neurochem's unique technology platforms.

Today, Neurochem operates using a team of nearly 200 researchers, management and staff--all dedicated to the advancement and development of its breakthrough technologies through clinical trial and commercialization phases.

Neurochem is currently negotiating a variety of international R&D agreements, partnerships, collaborations and contracts with renowned scientists, researchers, academic institutions, pharmaceutical companies as well as contract research organizations, without sacrificing full ownership of its therapeutic rights.

Products and Services:
Neurochem’s ultimate goal: To provide solid, viable therapeutic answers vital unmet medical needs, principally for neurological diseases. Neurochem has made even more significant advances on its lead product candidates, which are at various stages of development and all of them share the common purpose of the company.

Regarding research and development programs, Neurochem is at the forefront of research on neurological diseases.

AA amyloidosis: Kiacta (formerly known as Fibrillex Eprodisate disodium)
Neurochem's most advanced product investigational candidate is Kiacta, a product that was developed for the treatment of Amyloid A (AA) amyloidosis, a disease associated with chronic infectious or inflammatory diseases, including rheumatoid arthritis and Crohn's disease.

Alzheimer's disease: 3-amino-1-propanesulfonic acid Tramiprosate (Alzhemed)
Alzhemed is the Neurochem’s primary investigational product candidate being developed for the treatment of Alzheimer's disease (AD).

Hemorrhagic stroke due to cerebral amyloid angiopathy: 3-amino-1-propanesulfonic acid
(Tramiprosate; Cerebril) constitutes Neurochem's lead product candidate, a drug product that was created as a treatment of hemorrhagic stroke due to cerebral amyloid angiopathy (HS-CAA)

Key Personnel Facts:
Francesco Bellini: Chairman, Chief Executive Officer and President
Mariano Rodriguez: Chief Financial Officer; Vice President, Finance
Denis Garceau: Senior Vice President, Drug Development
Shona McDiarmid: Vice President, Intellectual Property
Andreas Orfanos: Executive Vice President, Strategic Planning and Scientific Affairs

Employees (2005): 192

Key Financial Facts:
Fiscal Year-End: December
Sales (2005): $3.8M
1-Year Sales Growth: 3,363.6%
Net Income (2005): $58.2M


Back to Top

 

Categories:

Biotechnology

 

Back to Top


 

 

   
Copyright © 2007 Biohealthmatics.com. All Rights Reserved. Contact Us - About Us - Privacy Policy - Terms & Conditions - Resources
Can't find what you are looking for? View our Site Map

Last Updated: 28 December 2007.